Innoviva, Inc. (INVA)
| Market Cap | 1.09B |
| Revenue (ttm) | 358.71M |
| Net Income (ttm) | 23.39M |
| Shares Out | 62.68M |
| EPS (ttm) | 0.36 |
| PE Ratio | 48.00 |
| Forward PE | 10.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 661,317 |
| Open | 17.26 |
| Previous Close | 17.33 |
| Day's Range | 17.25 - 17.60 |
| 52-Week Range | 14.33 - 21.28 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 55.00 (+216.46%) |
| Earnings Date | May 7, 2025 |
About INVA
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic o... [Read more]
Financial Performance
In 2024, Innoviva's revenue was $358.71 million, an increase of 15.54% compared to the previous year's $310.46 million. Earnings were $23.39 million, a decrease of -86.98%.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for INVA stock is "Buy" and the 12-month stock price forecast is $55.0.
News
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
Proceeds to be used to continue to advance development of Armata's phage product candidates LOS ANGELES , March 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or...
Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Innoviva: Underappreciated Strength In Hospital Therapeutics
Innoviva's strong balance sheet and stable royalty income from GlaxoSmithKline provide a solid foundation for its shift to specialty therapeutics, presenting an asymmetric risk-reward profile. The com...
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., (“IST”) a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution and lic...
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Innoviva to Participate in the UBS Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a biotechnology company focused on delivering innovative therapies in critical care and infectious diseases, announced today the...
Innoviva to Participate in Upcoming Investor Conferences
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's unique business model centered around royalties and healthcare assets.
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Innoviva to Participate in the BofA Securities Health Care Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that positive results from the Phase 3 oral zoliflodacin trial wi...
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 2024 /PRNewswire/ -- Armata Pharmaceuti...
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
10 stocks you can bet on being inflation-proof
New research shows that “quality” stocks — companies with high operating profitability but which are out of favor on Wall Street — are the type of stocks most likely to do well if inflation heats up. ...
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reporte...
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
GENEVA & WALTHAM, Mass.--(BUSINESS WIRE)--The Global Antibiotic Research & Development Partnership (GARDP), in collaboration with Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasda...
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today plans to present an oral abstract and four poster sessions from their p...
Innoviva: A Lot Of Moving Parts
Innoviva, Inc. is a biopharma company focused on the development and commercialization of pharmaceutical products. However, the company's main asset is royalty revenues that come from products it rece...